



January 9, 2024

**BSE Limited**

Department of Corporate Services,  
P. J. Towers,  
Dalal Street,  
**MUMBAI - 400 001.**

✓ **National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**Mumbai - 400 051.**

*Dear Sir/Madam,*

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 ('Listing Regulations').**

We are pleased to enclose a Press release regarding launch of Bromfenac Ophthalmic Solution, 0.07%, having received approval from the U.S. FDA.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS - 11973)**

**Encl: a/a**



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

## Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in the United States

*Being the first to file, Lupin is eligible for 180-day exclusivity period*

**Mumbai, Baltimore, January 09, 2024:** Global pharma major Lupin Limited (Lupin) today announced the launch of Bromfenac Ophthalmic Solution, 0.07%, after having received an approval from the United States Food and Drug Administration (U.S. FDA). Lupin is the exclusive first-to-file for this product and is eligible for 180-day exclusivity.

Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa® Ophthalmic Solution, 0.07%, of Bausch & Lomb Inc. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Bromfenac Ophthalmic Solution (RLD Prolensa®) had estimated annual sales of USD 182 million in the U.S. (IQVIA MAT November 2023).

### About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

Follow us on:

Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

**For further information or queries please contact –  
Heena Dhedhi**

Deputy General Manager – Corporate Communications

Email: [heenadhedhi@lupin.com](mailto:heenadhedhi@lupin.com)

### **\*Safe Harbor Statement**

Prolensa® is the registered trademark of Bausch & Lomb Inc.